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Abstract
For more than five decades, we have been refining advances in pancreas whole organ 
and islet cell transplantation as clinical therapies to treat the ever-increasing number of 
patients suffering from type-1-diabetes. Research and clinical practice have contributed 
to making both whole organ and cellular transplantation viable therapeutic options for 
a broader range of patients. Furthermore, both forms of clinical transplantation results 
have progressively improved, due to the ongoing refinement of organ donation and its 
various technical processes, combined with the evolution of immunosuppression and 
patient care now offering excellent long-term treatment for both type-1-diabetes and 
concomitant renal failure. This chapter provides an overview on how this has been 
undertaken and achieved over decades to ultimately provide outstanding outcomes on 
par with other organ transplantation results. Briefly, we cover the history of pancreas 
retrieval procedures, the importance of donor selection, the intricate processes of the 
organ donor operation, preservation of the pancreas, and the ideal ways to best improve 
outcomes for transplantation. Improving and providing the optimal donor and preserva-
tion conditions underpinning the success of subsequent whole pancreas or islet trans-
plantation as a safe, effective, and feasible therapeutic option for an increasing number of 
patients suffering from type-1-diabetes.
Keywords: diabetes, insulin, islet, islet cell, islet cell allotransplantation, islet cell 
transplantation, islet cell isolation, organ perfusion, organ retrieval, renal failure, type 1 
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1. Introduction
Since Kelly and colleagues performed the first whole pancreas transplant in 1966, significant 
advancements in pancreas transplantation have been made. [1] There was a gap following the 
first series of whole pancreas transplants due to poor graft outcomes with significant impact 
from poor organ preservation of the pancreas playing a major role. It took almost 20 years 
for the development of newer surgical techniques including use of newly developed perfu-
sion solutions, segmental grafts, advances in ductal drainage including bladder drainage, and 
effective immunosuppression regimens such that whole organ transplantation burgeoned, 
with great advances made by Sutherland and colleagues at the University of Minnesota [2]. 
However, it was not until much later following many years of experimental research that pan-
creata for islet cell isolation and transplantation became a reality. Over the past two decades 
in particular a great deal of effort has underpinned making islet cell transplantation a viable 
therapy for a broader range of patients with type 1 diabetes (T1D). Clinical results have pro-
gressively improved, now demonstrating outcomes on par with other organ transplants, spe-
cifically in terms of insulin independence, and graft and patient survival [3]. We are now at 
the point where islet cell transplantation, in the form of allotransplantation, like its forebear 
whole organ transplantation, has become widely accepted as a clinical therapy for patients 
affected by T1D.
Now more than five decades on and with many organ donor operations having been per-
formed since the advent of organ donor procedures as we know them, we have refined and 
perfected the organ donor process since the first organ retrieval of a brain dead donor in 1963 
[4] and the subsequent adoption of the “Acceptance of Brain Death for Organ Donation” 
issued by the Ad Hoc Committee of the Harvard Medical School [5]. We have seen an increas-
ing emergence of specialized organ retrieval teams with focus on the overwhelming need to 
improve organ donor rates for the ever increasing recipient patient population [6]. Always 
a dedicated surgical pursuit, research into organ donation and the surgical retrieval process 
for the pancreas and most other organs has often been overlooked in favor of recipient-
related research into the prevention of rejection, and improving immunosuppression and 
tissue matching. This is particularly problematic when it comes to whole pancreas and islet 
transplantation as the pancreas is a less retrieval tolerant organ than other solid organs, and 
requires extra attention both during and after retrieval to ensure that the organ’s valuable 
islets, which are especially susceptible to hypoxia and the ischemic insult, are effectively 
preserved [7, 8].
In this chapter we provide a general overview of Pancreas Retrieval for both Whole Organ 
and Islet Cell Transplantation, but it should be noted that there are clear overlaps in this 
process for both whole organ and cellular transplantation. As such the way the processes 
are performed can be utilized for retrieval for either type of subsequent transplant. Overall, 
we have seen significant improvements to pancreas transplantation results, in particular in 
the islet cell arena, due to the significant research undertaken to improve graft outcomes 
by improving donor selection and organ procurement and preservation [9]. On the recipi-
ent side we have also further improved outcomes with changes to the transplant and to the 
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pharmacological treatment of recipients such as newer focused monoclonal immunosup-
pressive strategies that better control graft rejection [9].
This chapter focuses on the optimal process for deceased donor pancreas retrieval and its role 
in maximizing graft function and survival. However, with a great number of processes to 
outline, only the major ones will be covered in this chapter. In particular, we will emphasize 
major improvements in donor selection, surgical retrieval techniques, pancreas retrieval in 
the context of multi-organ donors, back-table preparation of the pancreas, perfusion fluid 
types, and future perspectives including the utilization of technologies such as machine per-
fusion and persufflation. These factors will be discussed in the context of improved outcomes 
to the engraftment, function and survival of the transplants. It is also acknowledged that there 
remains the ongoing need for further improvements to both whole organ and islet cell trans-
plantation, however both techniques clearly offer safe and achievable therapeutic options for 
the ever-expanding number of patients suffering from T1D [10].
2. Historical timeline
The original retrieval processes of the modern era were initially developed for and used in 
kidney only retrieval surgery. As per Figure 1 the procedure first introduced in 1963 utilized 
cold lactated Ringer’s or low-molecular-weight dextran solutions infused directly into the 
renal artery of the retrieved kidneys, performed only after their removal from the donor [11]. 
These were the beginnings of modern donor retrieval but they were less than ideal techniques 
due to the time taken to perfuse the organs, and therefore a number of more active and by far 
more effective methods of perfusion and cooling of organs were subsequently developed in 
order to minimize ischemic insult and subsequent damage to organs. These techniques were 
based upon the concepts from cardiothoracic surgery, involving active patient cooling during 
procedures to prevent ischemic damage [12, 13]. The transplant fraternity quickly adopted 
these intravascular perfusion-related cooling techniques, which were standardly utilized as a 
first step in the preservation of all whole-organ grafts. The currently accepted modern cadav-
eric donor procedure is performed using some basal form of the ex situ techniques developed 
and performed in the mid to late 60’s by Starzl and colleagues [14] for not only kidneys but 
also incorporating the pancreas and liver. Further refinements saw the perfusion and addition 
of heparin to the perfusate solutions and also the donor. Ensuring removal of blood by ex situ 
perfusion as described by Belzer et al. [15] resulted in improved but only satisfactory kidney 
preservation of several days. However, this technique was eventually abandoned in most 
kidney transplant centers when it was learned that the quality of 2-day preservation was no 
better than with the simpler “iced slush” methods [16].
The underpinning method of iced slush for shipping was based around experimental work 
on kidneys [17]. This research and practice focused on perfusion fluids of differing intra-
cellular and extracellular fluids consisting of electrolytes with varying osmotic and oncotic 
effects that were infused into the allograft before placing it in a cold storage container. Collins 
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and colleagues developed a relatively simple technique (infusion of mannitol, phenoxyben-
zamine, and their Collins perfusate) providing good preservation in kidneys stored for up 
to 30 hours [17]. Other perfusates, such as Ringer’s lactate and 10% invert-sugar solutions, 
gave inferior results. The new perfusate solution and technique extended the time of simple 
ice storage from 12 hours to 30 hours. Continuous hypothermic perfusion saw further addi-
tions by Ackerman and Snell [18] and Merkel, Jonasson, and Bergan [19] who following many 
organ donor studies developed the widely accepted and much more simplified core cool-
ing. These utilized cold perfusion solutions with the infusion of the fluids being performed 
directly to the vascular bed of all the organs via the distal aorta and demonstrated signifi-
cant improvement for the pancreas but they were still less than ideal for this most sensitive 
organ. However, the development of these techniques used throughout the 70’s meant that 
organs could generally be removed without causing issues when retrieving multiple organs, 
which included the liver and sometimes pancreas. Kidney preservation became more feasible 
along with the other abdominal organs seeing times of 1 to 2 days, long enough to allow 
tissue matching and sharing of organs between hospital units even interstate or in Europe 
between countries. However, these were purely focused still on the kidneys rather than the 
other abdominal organs and as such a number of groups undertook experiments focusing on 
other organs including the pancreas and liver; landmark papers included those by Benichou 
Figure 1. A time line in the significant development of transplantation over the years with focus on the techniques used 
for whole pancreas and islet cell transplantation.
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et al. [20], using the Collins-Terasaki solution, and de Gruyl et al. [21] using cryoprecipitated 
plasma perfusion preservation of duct-ligated pancreatic allografts, along with Wall et al. [22] 
using similar plasma-like solution. This led directly to great improvements in pancreas and 
liver preservation and allowed organ sharing amongst transplant centers, although the pres-
ervation period was still limited to less than 8 hours.
The development of University of Wisconsin (UW) solution for organ preservation by Belzer, 
Jamieson, and Kalayoglu in the 1980s was a game changer in static organ preservation for 
transplantation [23]. This new flushout solution for preservation of the pancreas was tested 
in the dog model of segmental pancreas autotransplantation. The solution has an osmolality 
of 320 mOsm/L (K+ = 120 mM, Na + = 30 mM), and contains lactobionate, and raffinose as 
impermeants. The role of hydroxyethyl starch (HES), the colloid component of UW solution, 
was shown to be particularly important for pancreas preservation, in comparison to the liver 
and kidney [24]. UW perfusate solution preservation almost tripled the time of safe preserva-
tion of the various organs, including the pancreas, making national sharing of most organs a 
viable and practical process [25].
However, despite significant success the preservation or extended preservation of the pan-
creas still required further refinement, and significant research using animal models of static 
perfusion were pursued, in particular for use in islet cell transplantation. Along with perfusion 
fluids a number of standardly used retrieval techniques became more readily adopted [19]. 
However, until 1981 transplantation of the extra-renal organs was an unusual event such that 
the focus of perfusion only really focused on kidneys. By the mid-1980s, it became apparent 
that multiple organs would start to become transplanted in earnest, with liver, pancreas and 
thoracic organ transplant procedures becoming more widely accepted. A safe and effective 
method for multi-organ procurement and preservation was required by which the abdominal 
organs, kidneys, liver, and pancreas, could all be suitably retrieved using the same solution. At 
this stage Starzl and colleagues published an in-depth method on their “flexible procedure for 
multiple cadaveric organ procurement” [26], which was adopted by many centers worldwide.
However, even at this point the pancreas was often over-looked with the focus on the kidneys 
and liver as the principal organs to be retrieved. Starzl’s publication stated “If the whole pancreas 
is transplanted as we recommend, the combination of liver and pancreas removal is incompatible” and it 
was often the case when surgical teams were procuring the liver and pancreas together that there 
were issues relating to the suitable separation of their vasculature [27]. At this time, our own sur-
gical team also retrieved the pancreas with the liver, but always removed liver to the back-table 
before the pancreas and kidneys. The major perceived reason for this was the need for the life-
saving liver to take priority. Furthermore, as the portal vein and the branches of the celiac trunk, 
drain or supply both organs, preference was given to sacrificing the pancreas’ vessels instead of 
the liver. It was a number of years before this routine surgical practice would change.
Whole organ research utilized canine models as the dog pancreas is more anatomically similar 
to humans in comparison to the tri-lobed porcine pancreas. These models allowed replication of 
the clinical situation and further refinement of the retrieval and transplant procedures [28, 29]. 
From these came the widespread implementation of newer perfusion fluids such as UW 
solution, and the utilization of vascular extension grafts to the pancreatic vasculature helped 
resolve the situation of shortened pancreatic inflow and outflow conduits due to preference to 
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the liver in combined retrievals [30]. The other major change to the procedure was the adop-
tion of an en bloc liver pancreas retrieval technique, where both organs were rapidly removed 
in a bloodless field post perfusion, then separated on the back-table. Furthermore, the sharing 
of organs from a common donor by recipient teams from different units became routine by the 
early-1990s, in particular due to the use of UW solution, which had clearly been shown to be 
a real advantage in pancreas retrieval both experimentally and clinically [31].
In the 1990’s the focus on research and advances relating to the retrieval process started to 
shift, with attention once again shifting to the perfusate solutions, which were thought to 
be especially impactful for islet cell transplantation. A number of groups also investigated 
additives to the perfusate solutions such as the use of antibodies to reduce inflammation and 
further improve graft outcomes, although this was met with limited success [32]. In the 2000’s 
it became generally accepted this was achieved via cannulation of the aorta alone, with or 
without additional access to the portal venous system with variations that have been seen 
specifically in relation to multiorgan retrieval where some groups chose to perform ‘dual’ 
perfusion technique which are all discussed in greater detail later in this chapter [33, 34].
3. Use of the pancreas for whole organ or cellular transplantation—
donor selection
Underpinning the entire transplantation process, regardless of whether the donor is for whole 
pancreas or islet cell transplantation, is appropriate donor selection such that the donor organ 
is of a suitable size and quality to allow for use in either type of therapy. In order to be 
utilized in clinical transplantation, it is imperative that the donor be appropriately screened 
to ensure the organ to be retrieved is free from any disease that may subsequently man-
ifest in the donor, including cancer, and infections with viruses, bacteria, fungi, or prions 
[9]. It is paramount that we avoid the more commonly occurring diseases when screening 
the donor before accepting the pancreas for organ donor retrieval and subsequent clinical 
transplantation. Infectious risk factors depend on the history of patient, any underlying dis-
ease of the organ donor, and the immunosuppressive treatment administered to the recipient 
[35]. Transmission of most pathogens is possible, but their frequency varies according to the 
endemic population from the transplanted organ, the selected immunosuppressive therapy 
and prophylaxis utilized in the recipient, and also at the donor procedure [36]. Obviously, 
there are many more variables with regards to organ donor selection criteria, and these will 
be discussed in more detail in the following sections.
4. Pancreas retrieval
4.1. Surgical techniques
Pancreas retrieval for both whole organ and cellular transplantation necessitates meticulous 
surgical technique. In comparison to the liver and kidneys, the pancreas is more commonly 
damaged at retrieval, which subsequently results in non-utilization of a significant proportion 
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of procured pancreata [37]. The organ must be procured without any parenchymal and/or 
capsular breach, and its arterial inflow and venous outflow vessels must be clearly identified 
(tagged) and maintained for subsequent back-table reconstruction when used for whole pan-
creas [38]. The extent of organ and vascular dissection depends upon whether the retrieval 
is from a brain-dead (DBD) or circulatory death (DCD) donor; a large proportion of pan-
creas dissection can be undertaken in the warm phase for DBD donors, whilst pursuit of the 
DCD pathway necessitates wholly cold-phase dissection, which is potentially more difficult 
as appropriate anatomy is harder to identify.
4.1.1. Anatomical considerations
The pancreas is situated in the retroperitoneum, nestled within the curvature of the duode-
num. Important relations are both kidneys posteriorly, the spleen laterally and attached to 
the pancreas via its pedicle contained within the lienorenal ligament, the superior mesenteric 
vessels, bile duct, and portal vein in the region of the pancreatic head/neck, the inferior vena 
cava (IVC) deep to the head and portal vein, and the aorta, left suprarenal gland and left 
renal vein deep to the body. Pancreatic blood supply is primarily derived from the celiac 
artery in origin via the splenic and superior mesenteric arteries (via the inferior pancreatico-
duodenal artery), and also the gastroduodenal artery (via the superior pancreaticoduodenal 
artery). The celiac trunk gives off the splenic artery, which emerges at the upper pancreatic 
border and runs along this border in a tortuous fashion until turning towards the splenic 
hilum within the lienorenal ligament. The superior mesenteric artery (SMA) emerges from 
the aorta inferior to the celiac trunk, and is directed inferiorly on the posterior aspect of the 
pancreatic neck, to then lie on the uncinate process and then the 3rd part of the duodenum 
prior to entering the root of the mesentery. Venous drainage occurs via the splenic vein for a 
large part of the pancreas, whilst the superior and inferior pancreaticoduodenal veins drain 
the head into the superior mesenteric vein (SMV) and portal vein confluence. It is the shared 
vasculature of the pancreas with the liver that often causes retrieval issues as the origin of the 
splenic artery is from the celiac, and the outflow of the splenic vein is through the portal vein, 
necessitating delicate surgical dissection and care in separation to ensure shared and usable 
vasculature for both organs [39].
4.1.2. DBD retrievals—pancreas-specific considerations
Pancreas retrieval in the DBD donor is a controlled process that allows significant preliminary 
organ and vascular pedicle dissection. The Cattell-Braasch maneuver is utilized to expose the 
aorta and IVC distally, with the proximal extent of dissection limited by the SMA overlying the 
left renal vein; this maneuver will incorporate mobilization of the small bowel mesentery and 
pancreatic head/duodenum [40]. Our approach to exposure and dissection of the remaining 
pancreas [41] is to access the lesser sac by mobilization of the greater curvature of the stomach; 
the greater omentum is detached at its origin using ultrasonic shears (Harmonic Scalpel) as 
per Figure 2. The short gastric vessels are also detached using this method at the upper por-
tion of the greater curvature. The splenic flexure of the large bowel can thence be mobilized 
onto the lower pole of the spleen. Once the spleen is free of its surrounding attachments, it can 
be lifted and used as a handle to mobilize the tail and body of the pancreas without directly 
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handling the pancreas itself. The Harmonic Scalpel is also very useful in the dissection of the 
superior and inferior pancreatic borders, particularly the relatively vascular splenic flexure of 
the colon. The posterior surface of the pancreas can be mobilized with standard electrocautery 
in a relatively bloodless plane. The SMA/SMV pedicle inferior to the pancreas needs to be skel-
etonized such that it can be divided using a vascular stapler prior to pancreas removal in the 
cold phase. Superiorly, the bile duct is ligated and transected proximal to the point of ligation; 
residual bile is flushed out its open proximal end using saline instilled into the gallbladder. We 
will also free attachments around the gastroduodenal junction and duodenojejunal flexure, 
which are then identified with circumferential vessel loops for stapled division later in the 
cold phase. The inferior mesenteric vein is ligated in situ post perfusion as subsequent retrac-
tion of the divided vessel may make it difficult to identify on the back-table. Diluted povidone-
iodine solution is instilled into the duodenum via a nasogastric tube as a decontamination 
step, and is subsequently removed through the same route. Some authors report concerns 
with subsequent duodenal mucosal toxicity related to instillation of povidone-iodine, and 
Figure 2. The harmonic scalpels utilization during pancreas procurement. (A) Mobilization of the greater curvature 
of the stomach, (B) creation of the superior mesenteric pedicle (cold phase), and back-table separation of (C) the liver-
pancreas block, and (D) the pancreas and spleen.
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suggest additional back-table flushing of the duodenum with an alternate solution [42, 43]. 
Alternatively, duodenal decontamination can be completed using an antibiotic solution, such 
as amphotericin [40]. However, the most important factor is to utilize a decontamination pro-
cedure to reduce the potential risk of cross infection to the recipient. Our own unit has utilized 
povidone-iodine solution instilled into the duodenum via a nasogastric tube as a decontami-
nation step in more than 500 SPK transplants at our own center with no duodenal mucosal 
toxicity identified [44]. In the cold phase the duodenum is then divided above and below the 
pancreatic head with a linear cutting stapler, after carefully withdrawing the nasogastric tube 
from the duodenum into the body of the stomach. Any remaining superior mesenteric pedicle 
dissection is also completed, and a vascular (cutting) stapler is utilized to divide this pedicle. It 
is of paramount importance that the pancreas is not injured during this step as this will cause 
serious issues in both whole organ and islet cell transplantation. Furthermore, if the mesen-
teric pedicle is divided too close to the pancreas, or includes part of the uncinate process, there 
is a risk that blood supply to the pancreatic head via the inferior pancreaticoduodenal branch 
of the SMA will be compromised, creating a significant problem for whole organ transplanta-
tion [40, 45, 46]. Additionally, for the whole organ transplant an arterial and venous conduit 
should be retrieved for back-table pancreatic vascular reconstruction. This usually consists of 
a segment of the external iliac vein for use as a portal vein extension graft if required, and the 
common iliac artery bifurcation, including a length of the internal and external iliac arteries, to 
fashion a Y-graft connecting the native SMA and splenic artery. It is essential that the common 
iliac bifurcation is not damaged during this process [45]. Like a number of other major units 
our center preferentially retrieves the pancreas en bloc with the liver, with separation of both 
organs performed on the back-table (see below) [47].
4.1.3. DCD retrievals
DCD pancreas retrieval is technically feasible, and can achieve excellent outcomes in selected 
donors certainly in the whole organ arena (see Outcomes, below). In contrast to DBD pro-
curement, the first step in all DCD retrievals after a rapid laparotomy is cannulation and cold 
perfusion via the aorta [48, 49]. Venous venting is conducted via the IVC. Alternatively, if 
local laws allow, an in situ flush can be achieved using femoral cannulae inserted prior to the 
withdrawal of life support [49, 50]. Ante-mortem interventions including heparinization have 
been shown to also provide significant improvements to pancreas retrieval outcomes in the 
DCD setting [51]. Standard pancreas retrieval can then be undertaken as described for DBD 
donors, although donor hemostasis is no longer a concern and therefore sharp dissection is 
commonly utilized. The use of energy devices such as the Harmonic Scalpel at this stage may 
help minimize recipient bleeding however, as described in the DBD setting.
4.1.4. Pancreas retrieval and multi-organ donors
Pancreas retrieval is almost never undertaken in isolation, but rather it is usually procured 
in the context of a multi-organ retrieval, often in the presence of multiple retrieval teams. 
Meticulous retrieval technique therefore needs to be maintained and balanced in the pres-
ence of these competing factors, especially in the presence of concomitant liver procurement, 
which is still given preference owing to the critical requirement of liver transplant recipients. 
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Pancreas-alone donors are uncommon in this day and age due to developments in procure-
ment and preservation techniques. Some authors raised concerns that combined liver-pan-
creas retrieval, in contrast to pancreas retrieval alone, resulted in significant “flush” injury to 
the pancreas owing to a higher volume of perfusion solution and the utilization of dual aorto-
portal cannulation in the combined donors [52]. However, other studies clearly demonstrated 
that multi-organ retrieval, including combined liver-pancreas retrieval, was not detrimental 
to pancreas transplantation outcomes [53–58]. Another factor that previously precluded com-
bined liver-pancreas procurement was aberrant hepatic arterial anatomy, in particular the 
presence of an aberrant or accessory right hepatic artery originating from the superior mes-
enteric artery [58]. Abandoning retrieval of the pancreas due to this situation is now rare, as 
a preserved length of the right hepatic artery originating from the SMA stump can effectively 
be anastomosed to the GDA as part of a back-table reconstructive procedure [45, 46]. It is only 
when the right hepatic artery is within the substance of the pancreas that whole pancreas 
retrieval should be precluded in favor of the liver [59] but the pancreas can still be retrieved 
for islet cell isolation as the pancreas can still be readily perfused, and on the back table the 
vessels readily separated, including if necessary taking them from the body of the pancreas 
[9]. However, if this is undertaken then care should be taken to not damage the parenchyma of 
the pancreas as this makes the distension of the pancreas with collagenase for digestion more 
difficult [9]. Over the last 25 years and more than 1000 retrievals the authors have never found 
any anatomical vascular anomaly to prevent an en bloc liver-pancreas retrieval, although this 
is cited as a common reason to decline pancreas retrieval worldwide.
4.1.5. Back-table separation of the liver-pancreas block and further back-table preparation of the 
pancreas
The combined liver-pancreas block is taken to the back-table for separation. The aortic seg-
ment is divided such that the proximal portion of the SMA remains with the pancreas, whilst 
the celiac axis remains in continuity with the liver. Superior to the pancreatic head, the portal 
vein is divided approximately 1 cm from the pancreas, whilst the splenic artery is divided 
closer to its emergence from the celiac axis [45, 46]. The GDA is ligated and divided prior to 
entering the pancreas; a longer length remains with the liver. The splenic artery and portal 
vein associated with the pancreas should be marked with a prolene suture to facilitate iden-
tification at the transplant center. The spleen is also routinely removed at the donor hospital, 
in addition to skeletonization of the pancreas prior to transportation. The Harmonic Scalpel 
is once again a useful tool that facilitates all pancreas-related back-table work if the graft is to 
be used for whole pancreas transplantation [41]. Limited back-table perfusion of the pancreas 
with UW solution is employed to ensure no blood is left within the organ or its vessels, whilst 
minimizing the risk of graft pancreatitis or edema.
In pancreas retrievals for islet cell isolation, the author’s use a similar en bloc technique, with 
careful mobilization of the pancreas prior to aortic cannulation as per Figure 3. However, there 
is no need for meticulous hemostasis post perfusion and it is not necessary to remove the bulk 
of the tissues as this can be performed at the islet isolation facility. At the isolation center, the 
duodenum, spleen, and connective, extracapsular and vascular tissues are removed from the 
pancreas prior to it being cannulated to allow infusion of the digestive collagenase enzyme for 
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Figure 3. Procurement of the DBD pancreas. (A) Skeletonization of the pancreas, using the spleen as a handle, (B) stapled 
division of the superior mesenteric pedicle, (C) liver and pancreas ready for en bloc removal, (D) division of the aorta, 
(E) pancreas appearance after back-table preparation (n.b. Portal vein and superior mesenteric artery), and (F) back-table 
packing of iliac conduits in preservation solution.
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islet cell isolation [9]. As such there is also no need for preservation of pancreas vasculature, 
which can be given wholly to the liver when separated on the back-table.
4.1.6. Pancreatic inspection and graft assessment
The pancreas must be closely inspected during the retrieval process, and any concerns 
regarding organ quality and/or integrity should be fully conveyed to the implanting sur-
geon. Graft assessment should include qualities inherent to the donor pancreas, in addition 
to any retrieval-related damage, and should be made both in situ and on the back-table as 
per Figure 3. The pancreas should be assessed for parenchymal damage, capsular breach, 
and/or hematoma(s). Furthermore, other important factors that may preclude further trans-
plantation individually or in combination should be identified, including fibrosis, mass(es), 
high intra-parenchymal fat content, calcification, edema, and/or significantly diseased arter-
ies [40, 46, 59]. It is important to note that much of this assessment is highly subjective, and an 
“acceptable” pancreatic appearance and/or texture will vary from center-to-center. Obviously 
some of the co-factors such as high intra-parenchymal fat content, calcification, edema, and/
or significantly diseased arteries do not preclude the pancreas from being used for cellular 
transplantation. As an example, high intra-parenchymal fat content has been shown to be an 
advantage when performing islet isolation. Additionally, calcification, edema, and/or signifi-
cantly diseased arteries do not affect the pancreas when used for islet cell isolation as all blood 
vessels and extraneous tissues are stripped from the pancreas prior to its use. The pancreas 
should not be discarded without direct consultation with the recipient team and exploration 
of its use for cellular transplantation if precluded from whole organ transplantation [9].
4.1.7. Packaging the organ for transport
Following perfusion, back-table dissection, and final inspection, the pancreas can then be 
packed into a suitable transport container along with perfusate solution to ensure ongoing 
exposure to cold preservation solution. Our unit uses the sterile triple plastic bag technique 
whereby the organ and a suitable volume of organ perfusion fluid is instilled into the first 
sterile plastic bag, without dilution from iced slush. All air is removed from the bag, prior to 
sealing it with a zip-tie or heavy tie. This bag is then placed inside a second sterile plastic bag 
filled with iced slush, ensuring close and adequate cooling of the perfusate-filled inner bag. 
These two bags are then placed inside a third sterile plastic bag that is securely sealed, double 
tied, and appropriately labeled to identify the organ and contents of the bags. Additional ves-
sels retrieved for back-table reconstruction of the whole pancreas may also be packed into the 
triple sterile plastic bag set with the pancreas, or alternatively are placed inside a sterile vessel 
jar filled with preservation solution as per Figure 3, which is then double-bagged in sterile 
plastic bags, the first of which contains iced slush. The sealed pancreas and vessels are thence 
transported in a suitable, insulated iced shipping container. The container is labeled with its 
contents along with the contact details for both the donor and recipient coordinators.
4.2. In situ perfusion and cold static preservation
The function of in situ perfusion of the pancreas, as with other organs, is to achieve rapid 
removal of residual blood, whilst simultaneously cooling the organ and exposing it to preser-
vation fluid media for subsequent cold static storage (CS).
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4.2.1. Perfusion route
In order to achieve adequate in situ pancreatic perfusion during abdominal organ perfusion 
as a whole, the aorta must be securely cannulated and flushed using pressure such that 
perfusion media can flow into the pancreas via the superior mesenteric, gastroduodenal, 
and splenic arteries. Once perfusion fluid has traversed the pancreas, it must be allowed to 
exit the donor’s vasculature via the systemic and/or portal routes to prevent graft edema. 
Aortic-only perfusion is routinely performed by our center, and subsequent venous vent-
ing is usually undertaken via the IVC in the thorax. In the event that dual aorto-portal 
perfusion is employed for combined liver-pancreas retrievals, portal venous access via an 
inferior mesenteric cannula can impede pancreatic outflow, and reduce the physiologic 
arterial-portal pressure difference that is required for pancreatic perfusion/flow [42, 60]. As 
such, in these cases, the portal vein may instead be accessed after dividing it superior to the 
pancreas, thereby also allowing unobstructed pancreatic venous drainage via the proximal 
aspect of the transected portal vein [60, 61]. A further back-table flush of the pancreas at the 
donor center is sometimes conducted via the splenic artery and SMA, although this step 
may be omitted [45, 62–65]. Evidence for or against either approach is currently lacking in 
both the case of whole pancreas and cellular transplantation. But preference in the cellular 
setting appears to favor not having any over-perfusion or edema as this can impede and 
dilute the infusion of the collagenase used for digestion of the pancreas in the isolation 
process [66].
4.2.2. Perfusion fluid types
In general, the same final fluid employed for the final in situ flush of the pancreas is then uti-
lized for preservation of the organ in a bag of cold preservation fluid (CS). The preservation 
fluid utilized must maintain the organ at a hypothermic temperature (0–4°C), whilst simul-
taneously ameliorating the consequences of cold ischemia and prolonged organ immersion 
in fluid. As such, cold organ preservation fluids should ideally have the following properties 
that aim to minimize and/or reverse cellular and subcellular processes occurring within the 
pancreas during CS:
• Disrupted ionic pumps and ion accumulation and/or depletion, with subsequent down-
stream effects;
• Mitochondrial dysfunction, including reversal of the electron transport chain, and succi-
nate accumulation;
• Altered redox potentials (RP);
• Cellular edema;
• Acidosis;
• Accumulation of reactive oxygen species (ROS);
• Adenosine triphosphate (ATP) depletion; and,
• Disruption in glycolytic pathways [67–69].
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There are multiple preservation fluids currently in existence. These can be broadly classified 
as those that are intracellular and extracellular/intermediate in nature, based largely upon 
the solution’s potassium content, or low viscosity compared to high viscosity solutions [70]. 
Common components include colloid and/or impermeants to counteract cellular edema, anti-
oxidants for protection against ROS generation, ATP precursors to allow replenishment upon 
reperfusion, and buffers to retard the acidosis attendant with organ ischemia [70].
University of Wisconsin (UW) solution remains the most popular pancreatic preservation 
fluid, and was initially developed specifically for this purpose [71]. It is an intracellular solu-
tion with a high potassium content and high viscosity as it contains hydroxyethyl starch, 
a particularly important component for pancreas preservation [24]. UW contains other 
components that fulfill many ideal criteria that should be exhibited by preservation fluids, 
including the addition of impermeants such as raffinose, the ATP precursor adenosine, and 
anti-oxidants such as allopurinol. [68] Histidine-tryptophan-ketoglutarate (HTK) is another 
commonly utilized preservation fluid for the pancreas. In contrast to UW, HTK it is an “inter-
mediate” solution with a significantly lower potassium and sodium concentration, thereby 
in effect preventing ongoing organ metabolism. HTK also has low viscosity, theoretically 
allowing higher flow rates, and the histidine component of HTK provides it with significant 
buffering capacity [68, 70]. The next most commonly studied and clinically utilized pancreas 
perfusion and preservation fluid is Celsior, which has similar potassium content to HTK in 
addition to containing histidine as a buffer. It differs from HTK in that it has much higher 
sodium content; furthermore, it incorporates some of the advantageous constituents of UW, 
including similar impermeants and one shared anti-oxidant [68, 70]. Most recently, the use of 
Institut Georges Lopez (IGL-1) solution has been reported in pancreatic transplantation [72]. 
This solution has similar constituents to UW, except the sodium and potassium concentra-
tions are reversed such that it more closely resembles the extra-cellular environment [68]. 
A number of other more recently developed perfusion fluids have shown good effect in the 
preservation of pancreata for islet cell transplantation in particular the ET-Kyoto perfusion 
fluid. This fluid has a high sodium:low potassium ratio, and contains trehalose to protect the 
cell membrane against hypothermia and the nitric oxide donor nitroglycerin that facilitates 
vasodilatation [73].
National guidelines and/or protocols differ with respect to recommended perfusion and pres-
ervation fluids for the pancreas [45, 60, 74, 75]. UW and HTK solutions are the two most 
frequently recommended solutions for pancreas retrieval by such guidelines, although their 
utilization and volumes vary significantly. UK guidelines stipulate that in situ UW perfusion 
must be undertaken for pancreas retrieval, whilst Eurotransplant, German, and Australia/
New Zealand guidelines allow for either UW or HTK. Furthermore, none of these guidelines 
preclude dual perfusion when the pancreas is being retrieved, although German standards 
stipulate portal venous perfusion via a catheter inserted directly into the portal vein above 
the pancreas/duodenum [45, 60, 74, 75]. The use of Celsior or IGL-1 solution has not yet been 
incorporated into major National or Regional guidelines, although both have been employed 
in the clinical context [64, 65, 72, 76].
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A “pre-flush” is defined as a crystalloid fluid, such as Hartmann’s solution, that is perfused 
in situ prior to the final flush/preservation fluid, such as UW. The pre-flush can be employed 
safely in pancreatic procurement, although it is not commonly utilized. The function of this 
pre-flush in the context of pancreas procurement is to potentially (1) reduce the amount of 
UW required, thereby reducing retrieval costs, and (2) to clear all blood from the vasculature 
such that any residual blood does not aggregate with the hydroxyethyl starch in UW [77, 78].
UW is traditionally perfused in much lower volumes in comparison to HTK, and this is also 
reflected in the various pancreas retrieval guidelines in existence. This is largely related to 
the higher viscosity of UW, in addition to the larger volume and time for HTK perfusion to 
achieve equilibration of electrolyte content with the extracellular milieu [79, 80]. Australian 
guidelines recommend a 2–4 L crystalloid/low viscosity solution in situ pre-flush, followed 
by a UW flush of at least 1–2 L; a volume range for HTK is not specified [45]. In contrast, 
UK guidelines state a UW flush of 50–70 ml/kg should be employed via the aorta, whilst 
Eurotransplant allows for 50–100 ml/kg UW or 150–300 ml/kg HTK [74, 75]. Published reports 
may deviate from this; perfusion volumes utilized in aortic-only perfusion range from 0.8–
5.6 L, 4.9–9.7 L, and 0.8–7.9 L for UW, HTK, and Celsior respectively [81].
4.2.3. Additive(s) to perfusate
Heparin is a standard additive to the in situ perfusion fluid during DCD organ retrievals, includ-
ing for the pancreas. Additionally, thrombolytics such as streptokinase or tissue plasminogen 
activator (tPA) can be added to the in situ perfusion fluid, or alternatively our approach is to 
directly inject tPA into the aorta before commencement of the cold in situ flush; the aim of this 
is to achieve a higher quality vascular flush through the clearance of microthrombi [82–84]. 
However no comparative evidence exists for or against the use of thrombolytics in DCD pan-
creas retrieval, although there is certainly enthusiasm for this approach [83, 85].
4.2.4. Two-layer method
Great focus has remained on improving the quality of pancreas transport to the islet trans-
plant centers, including novel ways to provide oxygen rich media to the graft whilst in cold 
storage during shipping. In late 1988 Kuroda et al. was the first to report the use of the Two-
Layer Method (TLM) for shipping of the pancreas prior to islet cell isolation [86]. The TLM 
uses a perfluorochemical (PFC) and the organ perfusion fluid; initially Euro-Collins’ solu-
tion was used but was replaced by UW solution. The benefits of the use of the PFC are due 
to it being a biologically inert liquid that acts as an oxygen-supplying media. A pancreas 
preserved using the TLM is theoretically oxygenated through the PFC and substrates are 
supplied by the UW solution. This allows the pancreas preserved using the TLM to generate 
adenosine triphosphate during storage, prolonging the preservation time [87]. Strong debate 
still remains over its benefits, if any, when compared to the use of UW solution during CS 
[88, 89] and a recent publication of guidelines recommended against the use of the TLM for 
preservation of the pancreas preceding islet isolation [85].
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5. Outcomes
5.1. Whole organ pancreas transplant outcomes
Vascularized pancreas transplantation outcomes have improved considerably over time. 
Although changes to immunosuppression and post-transplantation care can partly account 
for this, advances in retrieval surgery and organ preservation, in addition to better donor 
selection, are significant contributors [90, 91]. When exploring pancreas transplantation out-
comes, it is paramount to account for the type of transplant performed, as these are associ-
ated with differential graft success and survival rates. More specifically, outcomes must be 
considered based on whether a simultaneous pancreas-kidney (SPK), pancreas after kidney 
(PAK) transplant, or pancreas transplant alone (PTA) was performed. An exploration of gen-
eral pancreas transplantation outcomes is beyond the scope of this chapter, as the focus is on 
the specific impact of retrieval and preservation practices. Overviews investigating trends 
and recipient outcomes following pancreas transplantation have been published by others, 
including Dean et al., and Gruessner et al. [90–94]. In brief, the current expected 5-year graft 
and patient survival rates for pancreas (SPK) transplantation range from 73 to 82% and 89 
to 93%, respectively, in the US, UK, Eurotransplant region, and Australia/New Zealand [91, 
94–96]. Outcome differences are seen between SPKs, which have historically provided bet-
ter results, and PTAs and PAKs, due to important variations in the type(s) of recipients for 
each transplant type, technical differences in the transplantation procedure, and a differential 
ability to diagnose and treat rejection episodes [91]. SPK transplantation is by far the most 
commonly performed type of pancreas transplant but islet cell transplantation has also seen a 
great increase in acceptance and success.
5.2. Islet cell transplant outcomes
Like its forebear, islet cell transplantation outcomes have improved considerably over time. 
The most impactful change was seen with advances in immunosuppression, clearly shown 
by the success of the Edmonton trial [97], one that revolutionized the progress of the cellular 
transplant. Other factors have also continued to impact the field, including post-transplanta-
tion care, advances in retrieval surgery and organ preservation, in addition to better donor 
selection. In brief, the most recent presentation from the Collaborative Islet transplant registry 
(CITR), presented the combined world islet cell transplant data where they reported that over 
1055 allogeneic islet transplants have now been reported by 50 islet transplantation centers in 
Australia, Europe, North America, and Asia. Of these cases, islet transplant alone (ITA) was 
the most frequent procedure (n = 858) followed by islet after kidney (IAK) and simultaneous 
islet and kidney transplantation (SIK) (n = 197) [98]. More recently, according to outcomes 
of the Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by 
Severe Hypoglycemia, the primary end point of HbA1c < 7.0% was achieved by 87.5% of sub-
jects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% at both 1 and 2 years. 
Hypoglycemia awareness was restored, with highly significant improvements in Clarke and 
HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred [99]. This trial 
clearly demonstrated the significant improvements achieved in the outcomes of islet cell 
transplantation and its impact on those patients suffering from hypoglycemic unawareness.
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5.3. The impact of procurement practices and techniques
Pancreas procurement techniques can significantly impact subsequent transplantation out-
comes, and can also prove the difference between organ utilization and discard. In particular, 
there is ample evidence that factors such as en bloc retrieval, retrieval technique and graft 
handling, type(s) of instruments utilized, and perfusion routes are all important determi-
nants of graft function and transplant-related morbidity. Ensuring that pancreas retrieval is 
performed by an experienced pancreatic transplant surgeon can significantly minimize such 
retrieval-related complications and risks [100].
Pancreatic damage during retrieval is not uncommon, and may deem the organ unusable 
certainly for whole organ transplant. Although the rates are different between centers and 
of course depends upon the level of training of the surgeons performing the retrievals, a 
large UK registry analysis showed a greater than 50% rate of surgical damage in retrieved 
pancreata; furthermore, approximately 10% of grafts were subsequently discarded due to 
damage sustained at retrieval in this analysis [37]. This was further seen as a significant loss 
as the grafts were also not utilized for islet cell transplantation due to extended cold ischemic 
times as a result of ongoing referrals. Within the same series, parenchymal and/or vascular 
(arterial) damage at procurement contributed to significantly higher rates of subsequent graft 
loss if the pancreas proceeded to transplantation [37]. In order to minimize surgical retrieval 
damage it is best to ensure that the staff performing the surgery are at a more senior level, and 
therefore our unit always sends a senior experienced surgeon to all pancreas retrieval surger-
ies to ensure adequate training of junior staff and optimize graft quality.
Graft thrombosis is the most important technical cause of whole organ pancreatic allograft 
loss. Pancreas retrieval and surgical technique is a significant etiologic factor in the incidence 
of graft thrombosis [101–104]. Graft pancreatitis, which in itself is a significant risk factor for 
graft thrombosis, is another potentially catastrophic complication associated with morbidity 
and graft loss that is partly attributable to retrieval technique [100]. Excessive graft handling 
and poor retrieval surgical technique, including damage to the inferior pancreaticoduodenal 
artery, are commonly accepted causes of graft pancreatitis in the recipient. [100] The same 
contributing factors also have an impact on the organs when they are used for islet cell isola-
tion [9].
En bloc procurement of the liver and pancreas is associated with better recipient out-
comes owing to faster organ retrieval and therefore shorter warm ischemia times [58, 100]. 
Interestingly, in the aforementioned UK registry analysis between 2008 and 2012, although 
the vast majority of liver and pancreas retrievals were not performed en bloc, there was a trend 
favoring the en bloc approach with respect to reduced pancreatic retrieval injury [37].
In situ perfusion routes, in particular the utilization of dual aorto-portal perfusion in prefer-
ence to aortic-only perfusion, can impact both whole organ and cellular allograft outcomes. 
Dual perfusion is potentially associated with increased retrieval-related pancreatic injury 
through a combination of flush injury (increased perfusion volumes), and/or an obstruction 
of pancreatic portal venous outflow secondary to catheter placement within the inferior or 
superior mesenteric veins [52, 58]. This ultimately impacts on the pancreas that is retrieved for 
whole pancreas or cellular transplantation as it can cause a significant increase in edema, and 
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may be associated with a higher rate of graft pancreatitis in whole organ, and poorer isolation 
results due to collagenase dilution in the islet isolation process. Importantly, an aortic-only 
perfusion technique does not seem to compromise hepatic allograft outcomes, especially in 
the standard criteria DBD donors from which pancreata are usually retrieved, and therefore 
should be considered by retrieval surgeons in these circumstances especially in centers that 
retrieve grafts for both whole and cellular transplantation [34, 58].
Furthermore, the specific instrument-type employed for pancreatic dissection is an important 
determinant of the amount of pancreatic bleeding upon reperfusion in the recipient [46]. We 
have shown that ultrasonic shear (e.g. Harmonic Scalpel) utilization during pancreas retrieval 
allows the sealing of peri-pancreatic vessels that are otherwise easily missed, thereby con-
tributing to less bleeding and a reduced blood transfusion requirement after transplantation 
within the recipient [41].
5.4. The impact of perfusion and preservation fluids
Pancreas preservation by cold storage using University of Wisconsin solution has been the 
mainstay method used for pancreas transplantation over the past two decades. Other solu-
tions, such as HTK, Celsior, and SCOT 15, struggled to demonstrate any advantage for short-
term preservation periods. But the advent of clinical islet transplantation and the larger use of 
controlled DBD donors have prompted the transplantation community to develop methods 
for increasing pancreas graft quality while preventing ischemic reperfusion damage espe-
cially in the cellular arena. It has been thought that oxygenation by 1- or 2-layer methods 
during pancreas preservation, as well as the use of perfluorocarbons, may increase islet yield. 
Based on the former methods, there is a renewed interest in machine perfusion and oxygen-
ation in pancreas preservation for pancreas transplantation and islet cell preparation [105].
A recent systematic review and meta-analysis by our group compared the outcomes of 
whole organ pancreas transplantation based on the in situ perfusion and subsequent pres-
ervation fluid utilized (UW, HTK, or Celsior) [81]. Ischemia-reperfusion injury of the pan-
creas, as reflected by post-operative peak lipase levels, was significantly lower when UW was 
employed as a perfusion/preservation fluid in comparison to HTK, but there was no signifi-
cant difference in peak amylase. This pancreatic ischemia-reperfusion injury may translate to 
lower clinical graft pancreatitis rates when UW is used in comparison to HTK, although this 
is not a universal finding [106]. No significant disparity was observed in biochemical injury 
markers or graft pancreatitis rates between UW and Celsior [81].
As discussed above, post-transplantation graft thrombosis is a significant cause of graft loss. 
Thrombotic graft loss rates do not differ based on whether UW, HTK, or Celsior is used for in 
situ perfusion and preservation of the pancreas [81]. Furthermore, cumulative graft survival 
after first post-transplantation month does not favor UW over HTK, although a distinct trend 
favoring UW emerges at the 1-year mark [81, 106, 107]. A US registry analysis provided fur-
ther evidence for this, showing a significant association between HTK perfusion/preservation 
and graft loss, in comparison to UW [108]. In comparison, the use of Celsior is associated with 
similar 1-year graft survival rates to UW [64, 76].
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The comparative utility of each preservation fluid must also be considered in the context of 
additional donor and transplant-related factors. One important consideration when consid-
ering any possible superior preservation effects of UW is the expected pancreatic graft cold 
ischemic time (CIT). UW may especially be beneficial when CIT is greater than or equal to 
12 hours [106, 108]. Furthermore, as already mentioned previously, pancreas retrieval is usu-
ally undertaken in the multi-organ donor setting. The perfusion/preservation fluid utilized 
must therefore not compromise any abdominal organ additionally procured, especially the 
liver. There is conflicting evidence regarding the relative efficacy of UW, HTK, Celsior, and 
IGL-1 for liver preservation. Some authors suggest that HTK results in inferior graft survival 
in comparison to UW, whilst others have reported similar survival but a reduction in post-
liver transplantation biliary strictures when HTK is utilized [109, 110]. Overall, current cumu-
lative evidence does not suggest a significant difference between these four fluids, and further 
research in this area is required [34].
5.5. Donation after circulatory death (DCD) vs. donation after brain death (DBD) 
transplantation and the importance of donor selection
With careful selection of donors, excellent whole organ pancreatic transplantation outcomes 
can be obtained even after DCD transplantation. The Pancreas Donor Risk Index (PDRI) is 
a tool that incorporates donor and preservation-related risk factors, including DCD donors, 
prolonged preservation time, and high body mass index (BMI), in a risk model for subsequent 
graft failure [111]. This model has been utilized in both the North American and European 
settings [111, 112]. It is important to note however that such models must not be used in 
isolation, and donor pancreata with one or more risk factors, including DCD donors, can 
still be used to achieve good outcomes. Indeed, our center’s first DCD pancreas transplant 
was in 2007, and has been followed by a further six DCD pancreas transplants, all display-
ing good long-term graft function [84, 113]. Meta-analyses have shown equivalent graft and 
patient survival when comparing DBD and DCD pancreatic transplantation, although graft 
thrombosis rates are higher when DCD grafts are used [51, 114]. Importantly, this higher 
graft thrombosis rate can be abrogated when donor therapies such as systemic ante-mortem 
heparin administration are applied [51]. The use of younger donors, with a lower BMI, and 
low warm ischemic times, has contributed to the success of DCD whole organ pancreas trans-
plantation [84, 115].
There has, however, been more reserved interest in DCD in pancreas for cellular transplan-
tation as the perceived ischemic insult appears to have a much greater effect on the iso-
lated islets for cellular transplantation than when the whole pancreas is transplanted. This 
is largely because the entire reserve of islets remains intact in the whole organ graft rather 
than being removed, and a smaller proportion is transplanted in the cellular graft [66, 99]. 
However, a number of encouraging studies have shown varying success. Albeit from a more 
advantageous DCD setting allowing earlier intervention including cannulation of the donor 
and antemortem heparin administration, which has, been shown to be a distinct advantage in 
this setting [51]. One such report from the Japanese Islet Registry reported their findings from 
65 DCD islet isolations performed for 34 transplantations in 18 patients with T1DM. Despite 
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the fact that all recipients remained free of severe hypoglycemia, only three patients achieved 
insulin independence for 14, 79, and 215 days. HbA1c levels and requirement of exogenous 
insulin were significantly improved in all patients [116]. In the more traditional DCD set-
ting the Edmonton group have recently reported their findings comparing islet isolations 
from 15 DCD and 418 DBD donors performed between September 2008 and September 2014. 
Compared to DBD, pancreata from DCD were procured locally and donors required less 
vasopressive support (P < 0.001 and P = 0.023, respectively), but the other variables were 
similar between groups. The metabolic function was similar between DBD and DCD, as well 
as the mean decrease in insulin requirement at 1-month post-transplantation (DBD: 64.82%; 
DCD: 60.17% reduction, P = 0.517). These results support the broader use of DCD pancreata 
for islet isolation. However, a much larger DCD islet experience will be required to truly 
determine non-inferiority of both short and long-term outcomes [117].
6. Future perspectives
There has been considerable interest regarding the utility and advantages of dynamic pres-
ervation methods in comparison to CS alone for organs such as the liver, kidneys, heart, and 
lungs. The pancreas has not remained immune to attempts adapting such techniques during 
the post-procurement phase, although their current clinical success remains limited. Non-
static methods of preservation can potentially:
• Reduce graft discard by allowing more accurate graft assessment after retrieval in compari-
son to current methods, which are largely subjective; and
• Improve organ quality by reducing ischemia-reperfusion-related damage, including by the 
targeted delivery of pharmacotherapies aimed against ischemia-reperfusion injury, and 
also gene therapies and stem cells, into the pancreas.
6.1. Machine perfusion
Machine (ex vivo) perfusion (MP) entails cannulation and mechanical perfusion of the pan-
creas via its inflow vessels; perfusion fluid is re-circulated through the circuit for the duration 
of perfusion. Broadly, MP can be hypothermic, subnormothermic or normothermic, pulsatile 
or non-pulsatile, and continuous or for a limited proportion of the preservation/transport 
phase (e.g. pre-implantation). Current pancreatic MP work is lacking in the sphere of clinical 
transplantation, and is limited to pre-clinical animal and discarded human pancreas studies; 
only the latter will be the focus of this section, with experimental animal work summarized 
in detail elsewhere [118–120].
There are certain pancreas-specific issues that need to be considered with respect to MP that 
do not apply to other organs such as the kidney. Most importantly, the pancreas is a low-flow 
organ, and even relatively low pressures in a MP setup can result in significant graft edema 
and weight gain [121]. Furthermore, higher perfusion pressures can contribute to vascular 
thrombosis secondary to endothelial damage [120]. However, especially if MP is undertaken 
Organ Donation and Transplantation - Current Status and Future Challenges172
at normal body temperature (normothermic), such risks must then be balanced against the 
need for adequate perfusion to sustain normal aerobic metabolism. An additional challenge 
during pancreatic MP is the need to adequately and safely account for the organ’s exocrine 
output, which is stimulated during normothermic perfusion [122].
As a result of these issues, most pancreatic MP studies have been conducted in the field of 
islet cell transplantation rather than the whole pancreas [120, 123]. Graft edema, is disad-
vantageous for both whole organ and cellular transplantation. However some groups have 
studied its use as it theoretically facilitates the enzymatic digestion of pancreatic acinar tissue 
[124]. Hypothermic MP can potentially be employed to increase human islet yield, viability, 
and insulin secretion despite an extended CIT (> 12 hours), possibly increasing the number 
of pancreata that can be used for successful islet isolation [125]. Cases of human islet trans-
plantation following MP are yet to be published, however. Whole organ pancreas MP has 
been investigated in the context of extended criteria organs that were not utilized for human 
transplantation. Some authors have shown 6 hours of oxygenated hypothermic MP using UW 
machine perfusion solution increases the ATP content of DCD pancreata to reach a level that 
is similar to DBD pancreata at baseline [126]. Graft edema can be kept to a minimum if low 
pressure hypothermic MP is utilized, even for as long as 24 hours [127]. Subsequent ex vivo 
normothermic perfusion can be used to simulate reperfusion at transplantation after initial 
hypothermic MP, and has been shown to demonstrate adequate insulin secretion by such 
pancreata [128].
Normothermic MP is an attractive alternative for whole pancreas preservation, and likely pro-
vides better graft viability assessment than hypothermic perfusion. Both endocrine and exo-
crine graft function can be assessed during perfusion by measuring C-peptide and/or insulin 
secretion and stimulation in response to glucose, and amylase and lipase release, respectively 
[122, 129]. Blood flow and resistance parameters can also be assessed using this technique, 
although this is also possible with hypothermic MP. However it is important to note that no 
defined cut-offs or validated protocols for human transplantation have been developed, and 
will require significantly more pre-clinical work.
6.2. Persufflation
Persufflation is a technique in which the pancreas is directly perfused with a humidified gas 
such as oxygen via the SMA and/or splenic arteries. Non-utilized human DBD pancreata have 
been perfused by this method, and subsequent graft assessment showed an increase in pan-
creatic ATP levels [130]. Porcine data from the same group showed significantly improved 
pancreatic histology after 24 hours of persufflation in comparison to utilization of the TLM 
[131]. Islet isolation after 24 hours of persufflation, including in human pancreata, is likely 
increased, compared to other methods such as the TLM [132]. This was confirmed in a later 
study, whereby islets of sufficient quantity and quality for transplantation were isolated 
from all five human pancreata that underwent persufflation using 40% humidified oxygen 
perfused at 10–25 mmHg [133]. Similar to MP however, pancreas persufflation has not yet 
been followed by clinical islet and/or whole organ pancreas transplantation although some 
research is now underway by a limited number of groups.
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6.3. Normothermic regional perfusion
Normothermic Regional Perfusion (NRP) of the abdomen was initially utilized in Spain in the 
uncontrolled DCD setting, and has since been utilized in the controlled DCD setting in other 
European countries and Asia [134–138]. The donor’s systemic arterial and venous systems are 
rapidly cannulated, and an ex vivo pump/oxygenator system is used to maintain an effective 
artificial circulation of the abdominal viscera. Cerebral and thoracic perfusion is avoided by 
clamping the supra-celiac aorta. This system reduces the organ’s warm ischemic insult, and 
proposed benefits include facilitation of a more effective subsequent in situ cold flush, ATP 
replenishment, and reduced oxidative stress [139]. Current experience for NRP exists mainly in 
the sphere of kidney and liver transplantation. However, utilization of this technique for DCD 
pancreas preservation and transplantation is appealing, especially because DCD pancreata can 
have sustained, long-term graft function (as discussed above). Within the UK, five pancreata 
have been procured after initial NRP, resulting in two SPK transplants and one islet cell trans-
plantation [136]. In Spain, one NRP pancreas has been transplanted in the context of a con-
trolled DCD donor [140]. Future studies are required to more effectively classify evidence for 
this strategy, and define its comparative role or efficacy with respect to MP. In the DCD setting, 
NRP may prove to be a more feasible strategy than MP owing to the aforementioned difficulties 
of maintaining a pancreas on an ex vivo machine circuit, although no direct comparisons exist 
between the two methods.
7. Conclusions
This chapter outlines the numerous advances that have occurred over the past few decades in 
pancreas retrieval techniques for both whole organ and cellular transplantation. It clearly dem-
onstrates the improved outcomes in both whole pancreas and islet cell transplantation from 
significant improvements to organ donor selection and management, and organ perfusion and 
retrieval surgery. We have seen insulin independence rates for more than 10 years post-trans-
plant in both settings with minimal complications. Whole organ transplantation is obviously 
now a well-accepted clinical therapy for many patients worldwide. However, islet transplanta-
tion still has limited application to the broader population of patients with T1D due to its reliance 
on the availability of cadaveric donors and selection, isolation results and transplant engraft-
ment, the side effects of immunosuppression and issues associated with the requirement for life-
long immunosuppression. The future holds many interesting potential new therapies that may 
or may not yield appropriate and safe methods for treatment of type 1 diabetes. From what has 
been outlined in this chapter we can see that outcomes for patients have improved significantly. 
If, unfortunately, patients cannot be treated prior to the advent of their type 1 diabetes then they 
can still be treated by transplantation. Moving forward, researchers and clinicians have numer-
ous fronts and multiple strategies arising at different stages of development in which to be able to 
offer patients treatments tailored to them and their disease. In the foreseeable future, transplanta-
tion and in particular the focus on organ retrieval and organ preservation will play a significant 
role in further improving outcomes, particularly with newer technologies such as machine per-
fusion and normothermic regional perfusion. Such technologies are hoped to increase both the 
Organ Donation and Transplantation - Current Status and Future Challenges174
number of suitable whole pancreata, as well as their quality, which will simultaneously lead to 
improved islet cell numbers and function in the cell therapy sphere of Diabetes care.
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